JP2024544060A - Apol1のスピロ環式阻害剤およびこれを使用する方法 - Google Patents

Apol1のスピロ環式阻害剤およびこれを使用する方法 Download PDF

Info

Publication number
JP2024544060A
JP2024544060A JP2024532219A JP2024532219A JP2024544060A JP 2024544060 A JP2024544060 A JP 2024544060A JP 2024532219 A JP2024532219 A JP 2024532219A JP 2024532219 A JP2024532219 A JP 2024532219A JP 2024544060 A JP2024544060 A JP 2024544060A
Authority
JP
Japan
Prior art keywords
alkyl
independently selected
groups
optionally substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544060A5 (cg-RX-API-DMAC7.html
Inventor
ティモシー ジェイ. センター,
レスリー エー. デーキン,
ミン チェン,
スティーブン ディー. ストーン,
エレナ ドルギフ,
ジェシカ エイチ. オルセン,
ハオシュアン ワン,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2024544060A publication Critical patent/JP2024544060A/ja
Publication of JP2024544060A5 publication Critical patent/JP2024544060A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C07F7/0836—Compounds with one or more Si-OH or Si-O-metal linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024532219A 2021-11-30 2022-11-29 Apol1のスピロ環式阻害剤およびこれを使用する方法 Pending JP2024544060A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163284195P 2021-11-30 2021-11-30
US63/284,195 2021-11-30
PCT/US2022/051274 WO2023101981A1 (en) 2021-11-30 2022-11-29 Spirocyclic inhibitors of apol1 and methods of using same

Publications (2)

Publication Number Publication Date
JP2024544060A true JP2024544060A (ja) 2024-11-27
JP2024544060A5 JP2024544060A5 (cg-RX-API-DMAC7.html) 2025-10-30

Family

ID=84946826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532219A Pending JP2024544060A (ja) 2021-11-30 2022-11-29 Apol1のスピロ環式阻害剤およびこれを使用する方法

Country Status (7)

Country Link
US (1) US20250084094A1 (cg-RX-API-DMAC7.html)
EP (1) EP4440697A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024544060A (cg-RX-API-DMAC7.html)
CN (1) CN118632850A (cg-RX-API-DMAC7.html)
AU (1) AU2022401847A1 (cg-RX-API-DMAC7.html)
CA (1) CA3240523A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023101981A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025503737A (ja) * 2022-01-18 2025-02-04 メイズ セラピューティクス, インコーポレイテッド Apol1阻害剤及び使用方法
JP7909027B2 (ja) 2022-01-18 2026-08-20 メイズ セラピューティクス, インコーポレイテッド Apol1阻害剤及び使用方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
EP4097083A1 (en) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
EP4146633A4 (en) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びこれを使用する方法
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3897833T (lt) * 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
EP4097083A1 (en) * 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
EP4146633A4 (en) * 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025503737A (ja) * 2022-01-18 2025-02-04 メイズ セラピューティクス, インコーポレイテッド Apol1阻害剤及び使用方法
JP7909027B2 (ja) 2022-01-18 2026-08-20 メイズ セラピューティクス, インコーポレイテッド Apol1阻害剤及び使用方法

Also Published As

Publication number Publication date
AU2022401847A1 (en) 2024-06-06
WO2023101981A1 (en) 2023-06-08
CN118632850A (zh) 2024-09-10
CA3240523A1 (en) 2023-06-08
US20250084094A1 (en) 2025-03-13
EP4440697A1 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
AU2022401847A1 (en) Spirocyclic inhibitors of apol1 and methods of using same
JP2024543934A (ja) Apol1の阻害剤としての4-フェニル-2-(1h-1,2,3-トリアゾール-4-イル)ピペリジン-4-オール誘導体、およびそれを使用する方法
JP2025505200A (ja) Apol1の阻害剤としての2-メチル-4-フェニルピペリジン-4-オール誘導体、及びそれを使用する方法
JP2025505644A (ja) Apol1の阻害剤としての4’,5’-ジヒドロスピロ[ピペリジン-4,7’-チエノ[2,3-c]ピラン]誘導体、及びそれを使用する方法
CN116528864A (zh) 杂芳基甲酰胺化合物
CA2895426A1 (en) Bet-protein-inhibiting dihydroquinoxalinones
CA3179333A1 (en) Modulators of alpha-1 antitrypsin
TWI914378B (zh) 作為alk5抑制劑之嗒𠯤基胺基衍生物
JP2010521528A (ja) Cns活性化合物としてのインドリジン及びそのアザ類似誘導体
AU2020316643B2 (en) N-methyl, N-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases
EP3080125A1 (en) Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same
EP3271361B1 (en) Tricyclic heterocyclic compounds useful as inhibitors of tnf
US20100120730A1 (en) 6-benzyl-2,3,4,7-tetrahydro-indolo [2,3-c] quinoline compounds useful as pde5 inhibitors
CA2954218C (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
CA3029086C (en) Chiral heterocyclic compound with hedgehog pathway antagonist activity, method and use thereof
KR20170042711A (ko) 치환된 비시클릭 화합물
JP2022528919A (ja) Malt1阻害剤としての尿素誘導体
KR20180043289A (ko) 화합물
JP7863148B2 (ja) Nod様受容体タンパク質3の阻害剤として有用なフタラジン誘導体
TW201726651A (zh) 2,3,4,5-四氫吡啶-6-胺衍生物
TWI768781B (zh) 轉化生長因子-β受體抑制劑
US5109013A (en) 2-(2-substituted aminoethyl)-1,4-dialkyl-3,4-dihydro-1H-1,3,5]triazepino[3,2-a]benzimidazol-5(2H)-ones as muscle relaxants
EA053250B1 (ru) Производные 4-фенил-2-(1h-1,2,3-триазол-4-ил)пиперидин-4-ола в качестве ингибиторов apol1 и способы их применения
CN118574809A (zh) 作为apol1抑制剂的4-苯基-2-(1h-1,2,3-三唑-4-基)哌啶-4-醇衍生物和其使用方法
WO2025032440A1 (en) Klf2 inducing compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251022

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260807